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Prognostic Significance of Systolic Blood
Pressure Changes During Dobutamine-
Atropine Stress Technetium-99m
Sestamibi Perfusion Scintigraphy in
Patients With Chest Pain and Known or
Suspected Coronary Artery Disease
Marcel L. Geleijnse, MD, Abdou Elhendy, MD, PhD, Ron T. van Domburg, MSc,
Riccardo Rambaldi, MD, Ambroos E.M. Reijs, MSc, Jos R.T.C. Roelandt, MD, PhD,
and Paolo M. Fioretti, MD, PhD
To investigate the prognostic value of dobutamine stress-
induced changes in systolic blood pressure (BP) 418 pa-
tients (mean age 60 years, 238 men) with chest pain
and known or suspected coronary artery disease, who
underwent a dobutamine-atropine stress technetium-
99m sestamibi myocardial perfusion scintigraphic study,
were followed up for 25 { 15 months. Blood pressure
was measured by automatic sphygmomanometry every
3 minutes. A marked decrease and increase in systolic
BP from rest to peak were defined as changes of ¢20
mm Hg, and ¢30 mm Hg, respectively. Worst outcome
events were cardiac death (n 30), nonfatal myocardial
infarction (n  17), and hospitalization for congestive
heart failure (n  8). A decrease in systolic BP (preva-
lence 16%) was associated with older age and higher
baseline systolic BP. Fixed and reversible sestamibi per-
fusion defects and follow-up results were similar to pa-
tients without a systolic BP decrease. In contrast, an in-
crease in systolic BP (prevalence 24%) was associated
with younger age, lower baseline systolic BP, and with
absence of a history of prior congestive heart failure or
treatment with angiotensin-converting enzyme inhibi-
tors. Furthermore, these patients had fewer fixed per-
fusion defects and tended to have fewer annual event
rates (3.5% vs 7.5%, p0.10). In a multivariate model,
an increase in systolic BP was not an independent pre-
dictor for subsequent events. In conclusion, a dobuta-
mine-induced decrease in systolic BP is not associated
with fixed or reversible sestamibi defects or adverse
prognosis. An increase in systolic BP, however, is asso-
ciated with less fixed sestamibi defects and a tendency
toward less annual event rates. Q1997 by Excerpta
Medica, Inc.
(Am J Cardiol 1997;79:1031–1035)
Dobutamine stress technetium-99m sestamibimyocardial perfusion scintigraphy is a pharma-
cologic stress modality with diagnostic1–5 and prog-
nostic6 properties comparable to dobutamine stress
echocardiography. Previous dobutamine stress echo-
cardiographic studies have reported that dobuta-
mine stress-induced hypotension is—unlike exer-
cise—induced hypotension7–10 not related to new
or worsening wall motion abnormalities11–14 and the
presence or extent of coronary artery disease.11,12
Furthermore, a relatively small echocardiographic
study12 has supported these results with prognostic
data that were similar for the hypotensive and the
nonhypotensive group. To date, however, these find-
ings were not confirmed by myocardial perfusion
scintigraphic data. Also, it is not known whether a
substantial increase in systolic blood pressure (BP)
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reflects, as in exercise studies,15,16 less myocardial
damage and better prognosis.
METHODS
Patient selection: Over a 4-year period, between
November 1990 and October 1994, 418 consecutive
patients with chest pain were referred to the nuclear
cardiology laboratory at the Thoraxcentre for the
evaluation of suspected myocardial ischemia with
dobutamine-atropine technetium-99m sestamibi sin-
gle-photon emission computed tomographic imag-
ing. All patients were unable to perform an adequate
exercise test and none had prior heart transplantation,
significant congenital or valvular heart disease, un-
stable angina, or known primary dilated cardiomy-
opathy. Mean age of the patients was 60 { 12 years
(range 23 to 85); 238 were men (57%), 203 patients
(49%) had a previous myocardial infarction, and 55
patients (13%) had coronary artery disease without
known myocardial infarction. One hundred four pa-
tients (25%) had typical angina, 205 (49%) had atyp-
ical angina, and 109 (26%) had nonanginal chest
pain. At the time of the study 301 patients (72%)
were receiving antianginal therapy including b
blockers in 180 (43%).
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TABLE I Patient Characteristics of 418 Patients Studied With Dobutamine-Atropine Stress Sestamibi Scintigraphy
BP Fall ¢20 mm Hg
(n  65)
Others
(n  353) p Value
BP Rise ¢30 mm Hg
(n  101)
Others
(n  317) p Value
Age (mean { SD) 65 { 10 59 { 12 0.0002 54 { 12 62 { 11 0.0000
Men 38 (59) 200 (57) 0.7872 63 (62) 175 (55) 0.2050
Prior MI (history) 28 (43) 177 (50) 0.2951 49 (49) 156 (49) 0.9029
CHF (history) 13 (20) 69 (20) 0.9326 11 (11) 71 (22) 0.0112
Angina (history) 14 (22) 90 (26) 0.4977 25 (25) 79 (25) 0.9721
Hypertension (history) 32 (49) 147 (42) 0.2559 42 (42) 137 (43) 0.7726
b blockers 28 (43) 152 (43) 0.9935 42 (42) 138 (44) 0.7305
ACE inhibitors 12 (19) 85 (24) 0.3242 15 (15) 82 (26) 0.0224
Diuretics 16 (25) 70 (20) 0.3805 16 (16) 70 (22) 0.1767
Unless otherwise indicated, data are expressed as number of patients (%).
ACE  angiotensin-converting enzyme inhibitors; BP  blood pressure; CHF  congestive heart failure; MI  myocardial infarction.
Dobutamine stress test: Infusion rate was 10 mg/kg/
min for 3 minutes, increasing by 10 mg/kg/min every
3 minutes up to a maximum of 40 mg/kg/min. In
patients not achieving 85% of the predicted maximal
heart rate and without symptoms or signs of myo-
cardial ischemia, atropine was administered in ad-
dition to the maximal dose of dobutamine, starting
with 0.25 mg adminstered intravenously and re-
peated up to a maximum of 1.0 mg within 4 minutes
with continuation of dobutamine infusion. Through-
out dobutamine infusion the electrocardiogram was
continuously monitored (3 leads) and recorded (12
leads) at 1-minute intervals. Blood pressure was
measured and recorded by automatic sphygmoma-
nometry in the supine position at rest and at the end
of each dobutamine (or atropine) stage. A hypoten-
sive response was defined as a decrease in systolic
BP from rest to peak of ¢20 mm Hg, in accordance
with most previous studies.12–14 An increase in sys-
tolic BP was defined as an increase of ¢30 mm Hg
from rest to peak, also in accordance with previous
(exercise) studies.15,16 Reasons for interruption of the
test were: horizontal or downsloping ST-segment
depression 0.2 mV at an interval of 80 ms after
the J point compared with baseline, ST-segment el-
evation 0.1 mV in patients without previous myo-
cardial infarction, severe angina, a symptomatic re-
duction in systolic BP 40 mm Hg, hypertension
(BP 240/120 mm Hg), and significant tachyar-
rhythmias.
Perfusion imaging: At peak stress, 370 MBq of
technetium-99m sestamibi was injected intrave-
nously, while dobutamine infusion was continued for
at least 1 minute. Stress scintigraphic images were
acquired on average 1 hour after the termination of
the dobutamine infusion. For resting studies, patients
were reinjected with 370 MBq of technetium-99m
sestamibi ¢24 hours after the stress study. Image
acquisition was performed with a Gammasonics sin-
gle-head Orbiter Camera (Siemens, Des Plaines, Il-
linois). As described previously,6 the tomographic
views were grouped into 6 major segments: anterior,
septum anterior, septum posterior, inferoposterior,
lateral, and apical. Myocardial radiotracer uptake
was evaluated visually (with the assistance of cir-
cumferential profiles analysis, including the normal
values) for each of the 6 major segments both during
rest and stress with a 4-point scoring method (0 
normal, 1  equivocal or minimally reduced uptake,
2  moderately reduced uptake, and 3  severely
reduced or absent uptake).
Coronary angiography: Coronary angiography was
performed within 6 months in 164 patients (39%).
Significant coronary artery disease was defined as a
diameter stenosis ¢50% in a major epicardial artery
at quantitative coronary angiography.17
Follow-up: Follow-up data were obtained over a
25 { 15-month period (range 6 to 54 months) by
outpatient clinic assessment, review of case notes
and contacting the patient, general practitioner or
other hospitals when necessary. Outcome events
were death (defined as cardiac death), nonfatal myo-
cardial infarction, and hospitalization for congestive
heart failure. Follow-up was complete in 413 pa-
tients (99%).
Statistical analysis: Values were expressed as value
{ SD, when appropriate. Comparisons (2-tailed) of
patients with and without significant changes in sys-
tolic BP were performed with the Student’s t test for
continuous variables and chi-square test for discrete
variables. Differences in the p value 0.05 were
considered significant. Differences of 0.10 were
described as a tendency toward significance. Multi-
variate logistic regression using the BMDP pack-
age18 was performed to identify factors that were re-
lated to events. A forward and backward stepping
algorithm was used with a p value of0.05 to iden-
tify independent predictors for events.
RESULTS
Dobutamine-induced decrease in systolic blood pres-
sure: A decrease in systolic BP ¢20 mm Hg was
present in 65 patients (16%), and was associated with
older age (p0.001) and higher baseline systolic BP
(p 0.0001). Severe, symptomatic hypotension as a
test end point was present in only 4 patients (1%).
Gender, history of prior myocardial infarction or
congestive heart failure, and the use of b blockers,
angiotensin-converting enzyme inhibitors or diuret-
ics were not associated with a hypotensive systolic
BP response (Tables I and II). There were no signif-
icant differences between patients with and without
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TABLE II Hemodynamic, Sestamibi Scintigraphic, and Angiographic Data
BP Fall ¢20 mm Hg
(n  65)
Others
(n  353) p Value
BP Rise ¢30 mm Hg
(n  101)
Others
(n  317) p Value
Heart rate
Rest 71 { 17 69 { 13 0.2647 68 { 11 70 { 14 0.1930
Peak 132 { 17 135 { 17 0.2612 137 { 16 134 { 17 0.0841
Increase 61 { 19 66 { 18 0.0547 69 { 17 64 { 18 0.0082
Systolic blood pressure
Rest 151 { 23 136 { 22 0.0000 133 { 21 140 { 24 0.0040
Peak 119 { 25 154 { 29 0.0000 177 { 28 139 { 26 0.0000
Increase 033 { 14 18 { 22 0.0000 45 { 18 01 { 20 0.0000
Dobutamine dose 38 { 6 38 { 4 0.6519 38 { 4 38 { 5 0.6305
Atropine dose 0.58 { 0.30 0.58 { 0.28 0.9637 0.63 { 0.28 0.56 { 0.28 0.1557
Sestamibi scan
Fixed defect score 2.4 { 2.6 2.6 { 3.2 0.6263 1.9 { 2.5 2.8 { 3.2 0.0227
Reversible defect score 1.8 { 2.4 1.6 { 2.0 0.4550 1.4 { 1.8 1.7 { 2.2 0.2184
Total defect score 4.2 { 3.8 4.2 { 3.8 0.9881 3.3 { 3.3 4.4 { 4.0 0.0127
Coronary angiography
Total number 22 (34) 142 (40) 0.3330 38 (38) 126 (40) 0.7034
Normal arteries 6 (27) 34 (24) 0.7351 9 (24) 31 (25) 0.9079
Diseased arteries 16 (73) 108 (76) 0.7351 29 (76) 95 (75) 0.9079
Single-vessel disease 6 (27) 56 (39) 0.2736 15 (40) 47 (37) 0.8088
Multivessel disease 10 (46) 52 (37) 0.4265 14 (37) 48 (38) 0.8889
Apart from angiographic data, which are expressed as number of patients (%), data are expressed as mean { SD.
Abbreviations as in Table I.
TABLE III Clinical End Points at Follow-Up
BP Fall ¢20 mm Hg
(n  65)
Others
(n  353) p Value
BP Rise ¢30 mm Hg
(n  101)
Others
(n  317) p Value
Follow-up (mean { SD) 23 { 14 25 { 15 0.2024 31 { 15 23 { 14 0.0000
Cardiac events
Death 5 (8) 25 (7) 0.8610 5 (5) 25 (8) 0.3195
Death/MI 8 (12) 39 (11) 0.7677 7 (7) 40 (13) 0.1151
Death/MI/CHF 9 (14) 46 (13) 0.8582 9 (9) 46 (15) 0.1471
Unless otherwise indicated, data are expressed as number of patients (%).
Abbreviations as in Table I.
systolic BP decrease with respect to dobutamine and
atropine doses, fixed, reversible, and total sestamibi
perfusion defect scores, presence and extent of cor-
onary disease, and events during follow-up (Tables
II and III).
Dobutamine-induced increase in systolic blood pres-
sure: An increase in systolic BP ¢30 mm Hg was
present in 101 patients (24%) and was associated
with younger age (p 0.0001), lower baseline sys-
tolic BP (p0.005), absence of history of congestive
heart failure (p 0.02), absence of the use of angio-
tensin-converting enzyme inhibitors (p 0.03), and
a higher increase in heart rate (p 0.01) (Tables I
and II). Patients with this systolic BP response had
lower fixed (p 0.03) and total (p 0.02) sestamibi
perfusion defect scores. However, the reversible de-
fect score as well as the presence and extent of cor-
onary disease were similar for both groups. Cardiac
events during follow-up tended to occur less in pa-
tients with an increase in systolic BP, especially
when the longer mean follow-up period was taken
into consideration (Table III). Figure 1 shows that
the annual death rates were 2.0% in patients with
versus 4.0% in patients without an increase in sys-
tolic BP (p NS); the annual death or nonfatal myo-
cardial infarction rates were 2.7% versus 6.5% (p
0.10), respectively, and all event rates (death, non-
fatal myocardial infarction, hospitalization for heart
failure) were 3.5% versus 7.5% (p 0.10), respec-
tively. In a multivariable stepwise logistic regression
model (including the patient characteristics listed in
Table I, an increase in systolic BP, and fixed and
reversible perfusion defects), only age, gender, his-
tory of congestive heart failure, and the presence of
reversible defects were independent predictors of
clinical outcome (Table IV). An increase in systolic
BP was not an independent predictor.
DISCUSSION
Generally, dobutamine stress causes an increase
in heart rate, a reduction in systemic vascular resis-
tance, a reduction in stroke volume (after an initial
increase), and an increase in cardiac output.12,19,20
Previous dobutamine stress studies have shown that
as a net result, in general, there is a mild but signif-
icant increase in systolic BP.6,21 This would suggest
that, on average, an increase in cardiac output cor-
rects for the decrease in systemic vascular resistance.
Although the pathophysiology of hypotension dur-
ing dobutamine infusion has not been completely de-
1034 THE AMERICAN JOURNAL OF CARDIOLOGYT VOL. 79 APRIL 15, 1997
/ 2w1f 0914 Mp 1034 Wednesday Mar 19 12:34 AM EL–AJC (v. 79, no. 8 ’97) 0914
FIGURE 1. Annual event rates for the different systolic blood pressure responses. CHF  congestive heart failure; MI  myocardial
infarction; *The 101 patients with an increase in systolic BP ¢30 mm Hg tended to have less events (p 0.10) than the combined 317
patients without such a blood pressure response.
TABLE IV Independent Predictors of Cardiac Events
(odds ratios, 95% CI)
Death Death/MI Death/MI/CHF
Age 65 years NS 2.3 (1.1–4.8) 2.1 (1.0–4.3)
Male gender 2.4 (1.0–6.1) 2.3 (1.1–4.8) 2.6 (1.3–5.3)
CHF (history) 3.5 (1.6–7.8) 2.8 (1.4–5.5) 4.5 (2.4–8.4)
Reversible defects 2.1 (1.0–4.6) 3.0 (1.6–5.9) 1.9 (1.0–3.5)
Variables included in the model were the patient characteristics of Table I, an
increase in systolic BP, and fixed and reversible perfusion defects. Variables that
were not significant for any end point are not displayed.
CI  confidence interval; other abbreviations as in Table I.
fined, theoretically, it may result from (1) an inade-
quate increase in cardiac output to compensate for
an expected decrease in systemic vascular resistance,
and/or (2) a disproportionate decrease in systemic
vascular resistance. An inadequate increase in car-
diac output may be due to inadequate contractile re-
serve, severe ischemic left ventricular dysfunction,
or left-sided obstructive heart disease. Dynamic left
ventricular cavity obliteration due to strong inotropic
stimulation was proposed as an important cause for
reduced cardiac output and hypotension,22 especially
in patients with dehydration, but later studies could
not confirm this mechanism,14 and the proposed bo-
lus of saline before dobutamine22,23 did not prevent
cavity obliteration in a canine model.24 The second
mechanism, a disproportionate decrease in systemic
vascular resistance may be due to excessive sensitiv-
ity of the peripheral circulation to b2-receptor stim-
ulation, increased b2-receptor density (deconditioned
patients), or to a neurally mediated mechanism in
which vigorous myocardial contraction stimulates
the intramyocardial mechanoreceptors, resulting in
sympathetic withdrawal and enhanced parasympath-
etic activity (the Bezold-Jarisch reflex).25 Based on
the described mechanisms, mandatory for a marked
increase in systolic BP are (1) absence of dramatic
decrease in systemic vascular resistance, and (2) an
increase in cardiac output by increase in heart rate
and/or contractility.
The 16% prevalence of a hypotensive response in
this study is in agreement with that reported in pre-
vious dobutamine stress echocardiographic studies
with comparable hypotension definitions.12–14 In
agreement with these previous reports, hypotension
was associated with older age and higher baseline
systolic BP. The consistent absence of histories of
prior myocardial infarction or congestive heart fail-
ure, ischemia (whether assessed by stress echocar-
diography or perfusion imaging) or coronary artery
disease, and worse prognosis in this and other stud-
ies11–14,22,23,26 is strong indirect evidence of a dobuta-
mine-induced hypotension mechanism that is pri-
marily based on an excessive decrease in systemic
vascular resistance, instead of a mechanism princi-
pally involving inadequate cardiac output. Because
of the associations with older age and higher baseline
systolic BP, a diminished baroreceptor reflex could
play an additional role.27 Some investigators pro-
posed that b blockers offered some protection
against hypotension by blocking peripheral vasodi-
latory b2-receptors or diminishing vigorous contrac-
tion, resulting in less intramyocardial mechanorecep-
tor stimulation and dynamic obstruction.12 However,
as in most previously reported studies,11,14 b blockers
were not associated with a hypotensive response in
the present study. Atropine can, by its vagolytic ef-
fects, increase systemic vascular resistance and pre-
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vent the development of a vasovagal reflex. How-
ever, the addition and dose of atropine was similar
in both patient groups.
As mentioned before, a substantial increase in
systolic BP generally requires an adequate increase
in cardiac output. Patients without an increase in sys-
tolic BP were older, had lower increase in heart rate
(as a consequence of their lower target heart rate),
and had more fixed sestamibi perfusion defects, in-
dicating damaged myocardium, with probably less
contractile reserve. Additional evidence for a mech-
anism involving inadequate contractile reserve is the
higher prevalence of histories of congestive heart
failure in these patients. Hogue et al,28 although not
dealing with this issue, reported that none of the 13
patients with a systolic BP increase¢20 mm Hg had
histories of congestive heart failure, compared with
5 of 23 patients without such a systolic BP response.
Patients with a marked increase in systolic BP in the
present study had a 50% reduction in annual cardiac
events. We believe that this is further support for a
better contractile reserve in these patients, because
the extent and severity of fixed sestamibi perfusion
defects are known to be related to prognosis.6 The
more significant results in prediction of survival by
systolic BP response in exercise studies15,16 can be a
result of different (postmyocardial infarction) patient
populations and the presence of the Bezold-Jarisch
reflex, which will be more prevalent in patients
stressed with a strong inotropic agent such as do-
butamine, and in patients with preserved left ven-
tricular rest function and contractile reserve. Indeed,
this reflex will flaw the expected increase in systolic
BP in more ‘‘normal’’ patients. Angiotensin-con-
verting enzyme inhibitors were used more often in
patients without a substantial increase in systolic BP.
Apart from the accentuation of the vasodilatory ef-
fects of dobutamine, the more frequent use of these
medications probably reflect the higher incidence of
histories of congestive heart failure in these patients.
Clinical implications: It seems likely that a dobuta-
mine stress-induced decrease in systemic vascular
resistance plays a major role in the development of
hypotension. Patients with hypotension during do-
butamine stress are therefore not at higher risk for
future events. Patients with a marked increase in sys-
tolic BP, however, are probably those with good con-
tractile reserve (and without a marked decrease in
systemic vascular resistance) and potentially better
clinical outcome.
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